All News

For National Recovery Month, Drug Topics sat down with Jake Nichols, PharmD, MBA, to discuss what kinds of resources there are for pharmacists dealing with a substance use disorder.

Study findings raise concern about increased pain and disability, poorer pain self-management, and impaired quality of life during adolescence that can continue into young adulthood.

Check out this list of our top 10 stories from September 2024.

Senators sought to uncover why prices of Novo Nordisk’s GLP-1 receptor agonist semaglutide are significantly higher in the US compared with countries in Europe.

Catch up on important immunization news from the month of September.

Pharmacy professionals are at an increased risk of substance abuse due to many factors, but long-term recovery can be achieved with the help of specialized recovery networks.

The approval comes shortly after the FDA approved arimoclomol from Zevra Therapeutics to treat neurological manifestations of the disease in combination with miglustat.

Higher doses of buprenorphine may also be more effective against the increasing prevalence of fentanyl in the opioid crisis.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Henry and Jade Ranger of The Prescription Shoppe in Williamsburg, Virginia, discussed their practice and what it’s like operating a business together.

Check out these featured Drug Topics interviews from September 2024.

The monoclonal antibody was also approved for active non-radiographic axial spondyloarthritis and active ankylosing spondylitis.

Eroxon topical gel addresses a significant unmet need for men experiencing erectile dysfunction.

“Pharmacies are processing prescriptions, our supply chain is fully operational, and most importantly, the first patients are now receiving neffy,” said Eric Karas, CCO of ARS Pharmaceuticals.

LEO Pharma expects the regulatory review process to be completed in the second half of 2025.

Initiatives such as media campaigns and legislative rulings by the agencies have likely contributed to the decline.

Albert Dahan, MD, PhD, discusses how cebranopadol could fit into the broader landscape of pain management therapies.

In case you missed it, this week we had news about end-of-year PBM reform on the horizons, cebranopadol as a transformational new pain therapy, success in co-administration of RSV and shingles vaccines, and more.

Check out this recap of articles published on our sister sites during the past week.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

In its first move since the July interim report detailing pharmacy benefit manager practices, the FTC is now suing CVS Caremark, Express Scripts, and Optum Rx.

Zevra Therapeutics said it expects the therapy to be commercially available in the United States in 8 to 12 weeks.

Stephanie Sober, MD, MSHP, shares insights into the research that led to Opill’s FDA approval and its implications for women’s access to contraception.

“By encouraging active self-management using health coaching principles, the WalkBack intervention might be able to reduce the prevalence of recurrent low back pain and associated burden on health care systems,” wrote investigators.

Johnny Garcia, Senior Director of Policy at the Pharmaceutical Care Management Association, discussed the common misconceptions surrounding PBMs and their role within the supply chain.

Check out important updates from the FDA for the week of September 16.

Johnny Garcia, Senior Director of Policy at the Pharmaceutical Care Management Association, discussed ongoing issues within the pharmaceutical supply chain and his organization’s role within it.

Roche announced positive topline results from the phase 3 CENTERSTONE study that evaluated the efficacy of baloxavir marboxil for the reduction of direct flu transmission.

Compounded with lifestyle interventions, researchers compared liraglutide with a placebo to measure its efficacy amongst children under 12 years old.